Skip to content

F2G vs Solid Biosciences

F2G logo

F2G

The rare fungal disease company

106 employees · est. 1998 · Manchester, United Kingdom

VS
Solid Biosciences logo

Solid Biosciences

#TogetherWeAreSolid

161 employees · est. 2013 · Boston, United States

F2G is the older company (1998 vs 2013).

Side-by-Side Comparison

F2G Solid Biosciences
Founded
1998 older 2013
Headquarters
Manchester, United Kingdom Boston, United States
Employees
106 161
Industry
Biotechnology, Health Care, Pharmaceutical Biotechnology, Health Care
Funding Stage
Not tracked yet Post-IPO Equity
Total Funding
$267.42M $610.30M
Funding Rounds
13 9
Services
Development of Antifungal Therapies, Research and Development in Fungal Infections, Early Access to Investigational Therapies Gene Therapy Development, Clinical Trials, Research Collaborations, Licensing Opportunities, Manufacturing Infrastructure
Target Customers
Patients with Rare Fungal Infections, Healthcare Providers, Medical Researchers Patients with Rare Neuromuscular Diseases, Patients with Cardiac Diseases, Medical Researchers, Healthcare Providers, Biotechnology Collaborators
Taxonomy
BiopharmaceuticalClinical-stageFungal DiseaseOrotomidesAntifungal AgentsInvasive Fungal Infections +9 Precision Genetic MedicineGene TherapyRare Neuromuscular DiseasesCardiac DiseasesDuchenne Muscular DystrophyFriedreich’s Ataxia +9
Website
f2g.com solidbio.com
F2G logo

About F2G

F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developing therapies for life-threatening invasive fungal infections. Central to F2G's innovation is the cre...

Solid Biosciences logo

About Solid Biosciences

Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid, reflects their commitment to advancing gene therapy solutions for rare neuromuscular and cardiac dis...

Also comparing in this category

Comparing more than these two?

Get F2G, Solid Biosciences and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does F2G compare?

A PDF of F2G and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

F2G was founded in 1998, based in Manchester, United Kingdom, with 106 employees. F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developi. Solid Biosciences was founded in 2013, based in Boston, United States, with 161 employees. Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid,.
F2G has raised $267.42M and Solid Biosciences $610.30M. Latest stage: Solid Biosciences Post-IPO Equity.
Both work in Biotechnology and Health Care.

Compare F2G with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at F2G on 11 Mar 2026, and Solid Biosciences on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout